

Aurealis Pharma to Present at BioPharm America 10th Annual International Partnering Conference in Boston, September 26-27th 2017

Basel Switzerland, Kuopio Finland – September 20th 2017.

Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company at the 10th Annual International Partnering Conference in Boston on September 26-27th 2017.

The presentation is scheduled for:

- **Time: Tuesday, September 26th 2017 at 1:30 PM**
- **Location: Sheraton Boston Hotel, Boston, MA. Room: Republic A, Level 2**
- **Track: Cell and Gene Therapies**

“We are excited to present our recent progress and meet investors one-on-one. Our chronic wound lead product AUP-16 is now finalized and entering GLP safety and toxicity studies and the cancer lead AUP-5550 is in non-clinical efficacy studies” said CEO Juha Yrjänheikki.

About Aurealis Pharma

Aurealis Pharma is a Basel, Switzerland and Kuopio, Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to re-educate the distorted host immune microenvironment in chronic inflammation and cancer to its proper state. Company's technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue effectively, safely and economically to address the unmet medical need in chronic wounds and cancer.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma

Tel: +358 45 8433550

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)



AUREALIS PHARMA

Hochbergerstrasse 60C

CH-4057 Basel

Switzerland

www.aurealispharma.com

Microkatu 1

FI-70210 Kuopio

Finland